{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:37:29Z","timestamp":1778254649769,"version":"3.51.4"},"reference-count":56,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ19H160042"],"award-info":[{"award-number":["LQ19H160042"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background. Chemoimmunotherapy has become the first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC). Still, reliable biomarkers to identify patients who could benefit from this combined therapy remain uncertain. This study focused on elucidating the predictive significance of the monocyte-to-lymphocyte ratio (MLR) and establishing the prognostic nomogram for unresectable ESCC treated with chemoimmunotherapy. Methods. Data of clinical features, peripheral blood parameters, and treatment records were collected in unresectable ESCC patients who received PD-1\/PD-L1 inhibitors plus chemotherapy as the first-line treatment from September 2017 to August 2021. The nomogram based on MLR and clinical parameters for predicting the overall survival (OS) was developed and validated. Results. Out of 81 patients enrolled, patients with a lower MLR had significantly longer progression-free survival (PFS) and OS than patients with a higher pretreatment MLR (p = 0.0067; p = 0.00069). The OS nomogram integrating MLR, performance status (PS) score, and body mass index (BMI) achieved a C-index of 0.770 (95%CI 0.645\u20130.896). The area under the ROC curve (AUC) value of the nomogram predicting 12-, 18-, and 24-month OS rates were 0.855, 0.792, and 0.744, respectively, which were higher than the clinical TNM staging system or the MLR. Stratified by the nomogram-generated scores, three risk groups (low, moderate, and high) in survival curves manifested a distinct difference (p &lt; 0.0001). Conclusion. MLR emerged as an independent predictive factor for PFS and OS in treatment-naive unresectable ESCC patients treated with chemoimmunotherapy. The constructed nomogram of MLR and clinical parameters was a reliable model for prognostic estimation.<\/jats:p>","DOI":"10.3390\/curroncol29110702","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T04:39:59Z","timestamp":1669005599000},"page":"8937-8954","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1\/PD-L1 Inhibitors Combined with Chemotherapy"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-6042","authenticated-orcid":false,"given":"Xiaolu","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfeng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiong","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyu","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-5406","authenticated-orcid":false,"given":"Chenyu","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luntao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-0383","authenticated-orcid":false,"given":"Nong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.18.02122","article-title":"Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial","volume":"37","author":"Chen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/14737140.2020.1814149","article-title":"Development of chemotherapeutics for unresectable advanced esophageal cancer","volume":"20","author":"Imazeki","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_4","first-page":"235","article-title":"Treatment for unresectable or metastatic oesophageal cancer: Current evidence and trends","volume":"15","author":"Mohammad","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1245\/s10434-019-07727-8","article-title":"Clinical Implications of Conversion Surgery after Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma","volume":"26","author":"Miyata","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jrr\/rraa110","article-title":"Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma","volume":"62","author":"Ochi","year":"2020","journal-title":"J. Radiat. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of Camrelizumab vs. Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): Multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100380","DOI":"10.1016\/j.esmoop.2021.100380","article-title":"Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis with focus on the value of PD-L1 combined positive score","volume":"7","author":"Leone","year":"2022","journal-title":"ESMO Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti\u2013PD-1 Therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"doab063","DOI":"10.1093\/dote\/doab063","article-title":"PD-1 inhibitors in esophageal cancer: A systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm","volume":"35","author":"Whooley","year":"2021","journal-title":"Dis. Esophagus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamaoncol.2015.4685","article-title":"PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development","volume":"2","author":"Hansen","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_18","first-page":"75","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Marabelle","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.trecan.2021.01.010","article-title":"Gut Microbiota in Cancer Immune Response and Immunotherapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.21037\/tlcr-21-156","article-title":"Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab","volume":"10","author":"Boyero","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cncr.31778","article-title":"The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy","volume":"125","author":"Bilen","year":"2018","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"589022","DOI":"10.3389\/fonc.2021.589022","article-title":"Association of Lymphocyte-to-Monocyte Ratio with Survival in Advanced Gastric Cancer Patients Treated with Immune Checkpoint Inhibitor","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"638312","DOI":"10.3389\/fcell.2021.638312","article-title":"Inflammatory Markers Predict Survival in Patients with Advanced Gastric and Colorectal Cancers Receiving Anti\u2013PD-1 Therapy","volume":"9","author":"Fan","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4143\/crt.2020.1198","article-title":"Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.21873\/anticanres.13765","article-title":"Neutrophil\u2013to\u2013lymphocyte Ratio and Use of Antibiotics Associated with Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors","volume":"39","author":"Guo","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"834564","DOI":"10.3389\/fonc.2022.834564","article-title":"Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients with Anti-PD-1 Therapy","volume":"12","author":"Gao","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ctrv.2015.10.003","article-title":"Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis","volume":"41","author":"Nishijima","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e048324","DOI":"10.1136\/bmjopen-2020-048324","article-title":"Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: A systematic review and meta-analysis","volume":"11","author":"Jiang","year":"2021","journal-title":"BMJ Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.21037\/tcr-21-1760","article-title":"Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy","volume":"11","author":"Zhu","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s12935-021-02072-x","article-title":"Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma","volume":"21","author":"Wu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: An opportunity for combination with Cytokines?","volume":"7","author":"Blay","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41416-021-01391-0","article-title":"Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients","volume":"125","author":"Ko","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3892\/mco.2021.2259","article-title":"Tumor-infiltrating lymphocytes in tissue material combined with systemic lymphocyte inflammation in patients with colorectal cancer","volume":"14","author":"Jakubowska","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"108623","DOI":"10.1016\/j.intimp.2022.108623","article-title":"Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma","volume":"106","author":"Yin","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/cas.14541","article-title":"Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma","volume":"111","author":"Baba","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: Therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Balta, E., Wabnitz, G., and Samstag, Y. (2021). Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115736"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti\u2013PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00277-015-2438-4","article-title":"Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified","volume":"94","author":"Hwang","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14740\/wjon1225","article-title":"Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients with Advanced Non-Small Cell Lung Cancer","volume":"11","author":"Minami","year":"2020","journal-title":"World J. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tanaka, K., Nakamura, S., and Narimatsu, H. (2022). Nutritional Approach to Cancer Cachexia: A Proposal for Dietitians. Nutrients, 14.","DOI":"10.3390\/nu14020345"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Barone, I., and Giordano, C. (2021). Leptin and Beyond: Actors in Cancer. Biomolecules, 11.","DOI":"10.3390\/biom11121836"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Cortegana, C., L\u00f3pez-Saavedra, A., S\u00e1nchez-Jim\u00e9nez, F., P\u00e9rez-P\u00e9rez, A., Casti\u00f1eiras, J., Virizuela-Echaburu, J., de la Cruz-Merino, L., and S\u00e1nchez-Margalet, V. (2021). Leptin, Both Bad and Good Actor in Cancer. Biomolecules, 11.","DOI":"10.3390\/biom11060913"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cam4.4461","article-title":"Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy\u2014The Asahikawa Gastric Cancer Cohort Study (AGCC)","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1245\/s10434-018-6929-0","article-title":"A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study","volume":"26","author":"Tang","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.2147\/DDDT.S314723","article-title":"Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus","volume":"15","author":"Duan","year":"2021","journal-title":"Drug Des. Dev. Ther."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/702\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:42Z","timestamp":1760145702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/11\/702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["curroncol29110702"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29110702","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}